
Alpha Profiles · Company Profile
REGENERON PHARMACEUTICALS, INC.
Canonical company identity and public leadership record.
https://registry.alpha.ac/companies/regeneron-pharmaceuticals-inc
- Entity
- Public listing published
- Primary listing
- NASDAQ: REGN
- Verification
- Partially verified
- Last reviewed
- 2026-10-16T13:51:31.052224+00:00
Overview
Alpha's canonical identity and public leadership record for Regeneron Pharmaceuticals.
Canonical AEGIS identity graph
Executive leadership
Current, confirmed roles are shown only when both the person Profile and supporting source record satisfy the public projection boundary. A missing role is not evidence that it does not exist.
Executive team
6 public recordsExecutive Vice President, Co-Chief Scientific Officer
- State
- confirmed
- Effective
- Date not stated
- Confidence
- 95%
- Evidence
- SEC DEF 14A 0001308179-26-000340Apr 24, 2026
Executive Vice President, Finance and Chief Financial Officer
- State
- confirmed
- Effective
- Date not stated
- Confidence
- 95%
- Evidence
- SEC DEF 14A 0001308179-26-000340Apr 24, 2026
Executive Vice President and General Manager, Industrial Operations and Product Supply
- State
- confirmed
- Effective
- Date not stated
- Confidence
- 95%
- Evidence
- SEC DEF 14A 0001308179-26-000340Apr 24, 2026
Board co-Chair, President and Chief Scientific Officer
- State
- confirmed
- Effective
- Date not stated
- Confidence
- 95%
- Evidence
- SEC DEF 14A 0001308179-26-000340Apr 24, 2026

Chief Executive Officer
- State
- confirmed
- Effective
- From Feb 4, 2026
- Confidence
- 94%
- Evidence
- REGN 10-K executive officersFeb 4, 2026
Board co-Chair, President and Chief Executive Officer
- State
- confirmed
- Effective
- Date not stated
- Confidence
- 95%
- Evidence
- SEC DEF 14A 0001308179-26-000340Apr 24, 2026
Governance leadership
Boards & Committees
Board and committee assignments appear only when the canonical public projection retains a current role and supporting source. Unpublished records are not interpreted as absence.
Record as of Oct 16, 2026. Chair, executive office, Lead Independent Director and committee appointments retain their separate source roles. A complete board composition denominator and committee charters are not established by a partial roster.
Board roles
13 public records- State
- confirmed
- Effective
- From Jan 1, 2003
- Confidence
- 85%
- Evidence
- Regeneron Pharmaceuticals, Inc. DEF 14A 2026-04-24Apr 24, 2026
- State
- confirmed
- Effective
- From Jan 1, 2016
- Confidence
- 85%
- Evidence
- Regeneron Pharmaceuticals, Inc. DEF 14A 2026-04-24Apr 24, 2026

Lead Independent Director
- State
- confirmed
- Effective
- From Jan 1, 2010
- Confidence
- 85%
- Evidence
- Regeneron Pharmaceuticals, Inc. DEF 14A 2026-04-24Apr 24, 2026
- State
- confirmed
- Effective
- From Jan 1, 2022
- Confidence
- 85%
- Evidence
- Regeneron Pharmaceuticals, Inc. DEF 14A 2026-04-24Apr 24, 2026
- State
- confirmed
- Effective
- From Jan 1, 2023
- Confidence
- 85%
- Evidence
- Regeneron Pharmaceuticals, Inc. DEF 14A 2026-04-24Apr 24, 2026
- State
- confirmed
- Effective
- From Jan 1, 2001
- Confidence
- 85%
- Evidence
- Regeneron Pharmaceuticals, Inc. DEF 14A 2026-04-24Apr 24, 2026
- State
- confirmed
- Effective
- From Jan 1, 1988
- Confidence
- 85%
- Evidence
- Regeneron Pharmaceuticals, Inc. DEF 14A 2026-04-24Apr 24, 2026
- State
- confirmed
- Effective
- From Jan 1, 2016
- Confidence
- 85%
- Evidence
- Regeneron Pharmaceuticals, Inc. DEF 14A 2026-04-24Apr 24, 2026
- State
- confirmed
- Effective
- From Jan 1, 1991
- Confidence
- 85%
- Evidence
- Regeneron Pharmaceuticals, Inc. DEF 14A 2026-04-24Apr 24, 2026
- State
- confirmed
- Effective
- From Jan 1, 2023
- Confidence
- 85%
- Evidence
- Regeneron Pharmaceuticals, Inc. DEF 14A 2026-04-24Apr 24, 2026
- State
- confirmed
- Effective
- From Jan 1, 1988
- Confidence
- 85%
- Evidence
- Regeneron Pharmaceuticals, Inc. DEF 14A 2026-04-24Apr 24, 2026
- State
- confirmed
- Effective
- From Jan 1, 1991
- Confidence
- 85%
- Evidence
- Regeneron Pharmaceuticals, Inc. DEF 14A 2026-04-24Apr 24, 2026
- State
- confirmed
- Effective
- From Jan 1, 2017
- Confidence
- 85%
- Evidence
- Regeneron Pharmaceuticals, Inc. DEF 14A 2026-04-24Apr 24, 2026
Committees
5 public recordsMembership and chair roles are projected from current board seats. A chair is shown only when a stored chair flag says so.
Audit
- Chair
- George L. Sing
- Members
- George L. Sing (Chair); Anita J. Ryan
Compensation
- Chair
- Christine A. Poon
- Members
- Christine A. Poon (Chair); George L. Sing
Corporate Governance and Compliance
- Chair
- Anita J. Ryan
- Members
- Anita J. Ryan (Chair); Christine A. Poon; Craig B. Thompson
Digital Technology
- Chair
- Not stated
- Members
- Craig B. Thompson
Technology
- Chair
- Not stated
- Members
- Craig B. Thompson
Source record
Alpha canonical company public projection
Supports Company identity, Published leadership, Entity status boundary
Reviewed 2026-10-16T13:51:31.052224+00:00
REGENERON PHARMACEUTICALS, INC. Form 10-K (filed 2026-02-04)
Supports Official website
Reviewed 2026-08-29T22:22:03Z













